T900607 in Treating Patients With Gastroesophageal Junction Cancer
- Conditions
- Gastric Cancer
- Registration Number
- NCT00054249
- Lead Sponsor
- University Hospitals Seidman Cancer Center
- Brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
- Detailed Description
OBJECTIVES:
* Determine the response rate (complete and partial) in patients with previously treated gastric or gastroesophageal junction carcinoma treated with T900607. (Gastric carcinoma closed to accrual as of 02/04.)
* Determine the duration of response and time to disease progression in patients treated with this drug.
* Determine the pharmacokinetics of this drug in these patients.
* Determine the safety profile of this drug in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive T900607 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ireland Cancer Center
🇺🇸Cleveland, Ohio, United States
Ireland Cancer Center🇺🇸Cleveland, Ohio, United States